| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
12,750,000 |
| Market
Cap: |
184.24(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.77 - $20.32 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 12.5 |
| Insider 6 Months : 12.5 |
| Insider 3/6 Months : 25.4 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Co.'s product candidates include GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers; and granulocyte macrophage colony-stimulating factor immunoadjuvant, which is to improve monocyte and neutrophil cytotoxicity against melanoma tumor cells and to improve activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
68,600 |
68,600 |
96,450 |
225,574 |
| Total Buy Value |
$872,910 |
$872,910 |
$1,130,787 |
$2,406,697 |
| Total People Bought |
1 |
1 |
2 |
2 |
| Total Buy Transactions |
8 |
8 |
23 |
59 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mcwilliams David |
Director |
– • – |
2021-12-14 |
4 |
B |
$27.56 |
$5,512 |
D/D |
200 |
620,301 |
2.39 |
-46% |
|
| Daugherty Frank Joseph |
Chief Medical Officer |
• • – |
2021-12-14 |
4 |
B |
$26.99 |
$29,983 |
D/D |
1,111 |
88,121 |
2.81 |
-46% |
|
| Patel Snehal |
CEO and CFO |
• • – |
2021-04-13 |
4 |
B |
$36.98 |
$99,853 |
D/D |
2,700 |
1,189,539 |
2.81 |
8% |
|
| Hallock Kenneth |
Director |
– • – |
2020-11-24 |
4 |
B |
$5.39 |
$5,386 |
I/I |
1,000 |
397,004 |
2.1 |
871% |
|
| Daugherty Frank Joseph |
Chief Medical Officer |
• • – |
2020-11-23 |
4 |
B |
$5.10 |
$5,100 |
D/D |
1,000 |
87,010 |
2.81 |
811% |
|
| Hallock Kenneth |
Director |
– • – |
2020-11-20 |
4 |
B |
$5.37 |
$5,370 |
I/I |
1,000 |
396,004 |
2.1 |
697% |
|
| Rothe Eric |
Director |
– • – |
2020-11-20 |
4 |
B |
$5.40 |
$10,800 |
D/D |
2,000 |
313,226 |
2.39 |
697% |
|
| Mcwilliams David |
Director |
– • – |
2020-11-20 |
4 |
B |
$5.40 |
$8,100 |
D/D |
1,500 |
620,101 |
2.39 |
697% |
|
| Patel Snehal |
CEO and CFO |
• • – |
2020-11-19 |
4 |
B |
$5.40 |
$10,795 |
D/D |
2,000 |
1,186,839 |
2.81 |
543% |
|
| Patel Panjaj Amrit |
10% Owner |
– – • |
2020-11-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(561,798) |
0 |
|
- |
|
| Patel Kinnary |
10% Owner |
– – • |
2020-09-29 |
4 |
OE |
$0.00 |
$0 |
I/I |
129,400 |
129,400 |
|
- |
|
| Hallock Kenneth |
Director |
– • – |
2020-09-29 |
4 |
B |
$4.60 |
$38,353 |
I/I |
8,333 |
395,004 |
2.1 |
698% |
|
| Patel Snehal |
CEO and CFO |
• • – |
2020-09-29 |
4 |
B |
$4.60 |
$76,710 |
D/D |
16,667 |
1,184,839 |
2.81 |
698% |
|
| Patel Snehal |
CEO and CFO |
• • – |
2020-09-29 |
4 |
OE |
$0.00 |
$0 |
I/I |
1,360,635 |
129,400 |
|
- |
|
| Patel Snehal |
CEO and CFO |
• • – |
2020-09-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
304,489 |
1,168,172 |
|
- |
|
| Hallock Kenneth |
Director |
– • – |
2020-09-29 |
4 |
OE |
$0.00 |
$0 |
I/I |
116,575 |
386,671 |
|
- |
|
| Mcwilliams David |
Director |
– • – |
2020-09-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
171,622 |
618,601 |
|
- |
|
| Daugherty Frank Joseph |
Chief Medical Officer |
• • – |
2020-09-29 |
4 |
B |
$5.75 |
$9,999 |
D/D |
1,739 |
86,010 |
2.81 |
698% |
|
| Mcwilliams David |
Director |
– • – |
2020-09-29 |
4 |
B |
$5.75 |
$14,996 |
D/D |
2,608 |
446,979 |
2.39 |
698% |
|
| Hallock Kenneth |
Director |
– • – |
2020-09-29 |
4 |
B |
$5.75 |
$429,997 |
I/I |
74,782 |
257,368 |
2.1 |
698% |
|
| Patel Snehal |
CEO and CFO |
• • – |
2020-09-29 |
4 |
B |
$5.75 |
$657,495 |
D/D |
114,347 |
863,683 |
2.81 |
698% |
|
| Patel Kinnary |
10% Owner |
– – • |
2020-09-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,055,486 |
|
- |
|
| Thompson Jaye |
VP Clinical & Reg AffairsOffic |
• – – |
2020-09-24 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
252,810 |
|
- |
|
| Hallock Kenneth |
Director |
– • – |
2020-09-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
182,586 |
|
- |
|
| Thompson Jaye |
VPC AND REGULATORY AFFAIRSOffi |
• – – |
2020-09-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
140,450 |
|
- |
|
106 Records found
|
|
Page 4 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.30 (2.03%) 
